MapLight Therapeutics CMO Erin Foff sells $124,068 in stock

Erin Foff, the Chief Medical Officer at MapLight Therapeutics, sold 15,355 shares of the company's stock on October 15, 2026, resulting in a total sale value of $124,068. The shares were exchanged at an average price of $8.08 per share, with individual sales occurring between $7.755 and $8.3732. Since the stock has fallen to $7.70, trading near its 52-week low of $7.46, this sale was not a discretionary choice but rather a required action to meet tax withholding obligations related to the vesting of restricted stock units.

Following this transaction, Foff holds 296,906 shares of MapLight Therapeutics common stock. The stock currently seems undervalued, according to InvestingPro, and there are 15 additional ProTips available to subscribers for further insight into the company's situation. Additionally, MapLight Therapeutics recently secured a $150 million private placement financing, led by various institutional and accredited investors.

Despite this, analysts have expressed concerns, such as potential dilution from the capital raise and setbacks in trial data, which has affected the company's prospects in treating schizophrenia.